Saltar directamente a búsqueda Saltar directamente al índice A-Z Saltar directamente a navegación Saltar directamente a las opciones de páginas Saltar directamente al contenido del sitio

Referencias de las pautas sobre antivirales

Guía sobre el uso de agentes antivirales para la influenza

La información en esta página debe considerarse como actual para las prácticas clínicas de la temporada de influenza 2016-2017 en relación con el uso de medicamentos antivirales para la influenza.

Referencias actualizadas

Adisasmito W, Chan PK, Lee N, et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry. J Infect Dis. 15 de octubre de 2010; 202(8):1154-60. doi: 10.11/656316.

Academia Estadounidense de Pediatría. Comité de Enfermedades Infecciosas. Declaración de intenciones - Recomendaciones para la prevención y el control de la influenza en niños, 2014-2015..

Colegio Estadounidense de Obstetricia y Ginecología, Comité de Práctica Obstétrica. Opinión del Comité de ACOG Nº 468: vacunación contra la influenza durante el embarazo. Obstet Gynecol. 2010; 116(4): 1006--7.

Ayscue P, Murray E, Uyeki T, et al. Influenza-associated intensive-care unit admissions and deaths - California, September 29, 2013-January 18, 2014. MMWR. 2014; 63(7): 143-7.

Booy R, Lindley RI, Dwyer DE, Yin JK, Heron LG, Moffatt CR, Chiu CK, Rosewell AE, Dean AS, Dobbins T, Philp DJ, Gao Z, Macintyre CR. Treating and preventing influenza in aged care facilities: a cluster randomised controlled trial. PLoS One. 2012;7(10):e46509.

CDC. Prevención y control de la influenza con vacunas: recomendaciones del Comité Asesor sobre Prácticas de Inmunización (ACIP) - Estados Unidos, 2013-2014. MMWR. 2013; 62(RR-07): 1-43.

CDC. Inmunización del personal de atención médica: recomendaciones del Comité Asesor sobre Prácticas de Inmunización (ACIP). MMWR. 2011; 60 (RR-7); 1-45.

CDC. Pautas para prevenir la neumonía asociada a los cuidados de salud, 2003: recomendaciones de los CDC y el Comité Asesor sobre Prácticas de Control de Infecciones en los cuidados de salud. MMWR. 2004; 53(RR-3): 1-36.

CDC: Estrategias para la prevención de la influenza estacional en los cuidados de la salud..

Chan-Tack KM, Gao A, Himaya AC, et al. Clinical experience with intravenous zanamivir under an emergency investigational new drug program in the United States. J Infect Dis. 2013; 207(1): 196-8.

Chartrand C, Leeflang MM, Minion J, Brewer T, Pai M. Accuracy of rapid influenza diagnostic tests: a meta-analysis. Ann Intern Med. 3 de abril de 2012;156(7):500-11.

Chen LF, Dailey NJ, Rao AK, Fleischauer AT, Greenwald I, Deyde VM, Moore ZS, Anderson DJ, Duffy J, Gubareva LV, Sexton DJ, Fry AM, Srinivasan A, Wolfe CR. Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients--North Carolina, 2009. J Infect Dis. 15 de marzo del 2011; 203(6):838-46.

Chowell G, Viboud C, Simonsen L, et al. Impact of antiviral treatment and hospital admission delay on risk of death associated with 2009 A/H1N1 pandemic influenza in Mexico. BMC infectious diseases 2012; 12: 97.

Coffin SE, Leckerman K, Keren R, Hall M, Localio R, Zaoutis TE. El oseltamivir acorta el periodo de hospitalización de niños con influenza estacional grave: un estudio de cohorte retrospectivo. The Pediatric infectious disease journal 2011; 30(11): 962-6.

Comité de Enfermedades Infecciosas. Recomendaciones para la prevención y el control de la influenza en niños, 2013-2014. Pediatría. 2013; 132(4): e1089-104.

Comité de Enfermedades Infecciosas. Recomendaciones para la prevención y el control de la influenza en niños, 2014-2015. Pediatría. 2014; 134(5): e1503-19.

de Jong MD, Ison MG, Monto AS, et al. Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients. Clin Infect Dis. 2014; 59(12):172-85.

de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006; 12(10): 1203-7.

Dobson J, Whitley R, Pocock S, et al. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials The Lancet 2015; DOI: http://dx.doi.org/10.1/S0140-6736(14)62449-1

Dulek DE, Williams JV, Creech CB, Schulert AK, Frangoul HA, Domm J, Denison MR, Chappell JD. Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus. Clin Infect Dis. 1 de enero del 2010;50(11):1493-6.

Earhart KC, Elsayed NM, Saad MD, et al. Oseltamivir resistance mutation N294S in human influenza A(H5N1) virus in Egypt. J Infect Public Health. 2009; 2(2): 74-80.

Ebell MH, Call M, Shinholser J. Efectividad del oseltamivir en adultos: un meta análisis de los ensayos clínicos publicados y no publicados. Medicina familiar 2013; 30(2): 125-33.

Eriksson CO, Graham DA, Uyeki TM, Randolph AG. Factores de riesgo de la ventilación mecánica en niños estadounidenses hospitalizados a causa de la influenza estacional y la influenza pandémica A 2009*. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World

Eyler RF, Heung M, Pleva M, et al. Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation. Farmacoterapia. Dic. de 2012; 32(12): 1061-9.

Eyler RF, Klein KC, Mueller BA. La farmacocinética de oseltamivir y oseltamivir carboxilato en un niño con enfermedad grave que recibe oxigenación por membrana extracorporal y hemodiálisis venovenosa continua. J Pediatr Pharmacol Ther. Abril de 2012; 17(2):173-6.

Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2011; 60(1): 1-24.

Administración de Alimentos y Medicamentos. Medicamentos antivirales para la influenza (gripe) e información relacionada.

Administración de Alimentos y Medicamentos. Medicamentos aprobados con evaluaciones de equivalencia terapéutica [10.2 MB, 1298 páginas].

Fry AM, Goswami D, Nahar K, et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. Lancet Infect Dis. Feb. de 2014; 14(2):109-18.

Gaur AH, Bagga B, Barman S, Hayden R, Lamptey A, Hoffman JM, Bhojwani D, Flynn PM, Tuomanen E, Webby R. Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. N Engl J Med. 2010 Jan 7;362(1):88-9.

Giraud C, Manceau S, Oualha M, et al. High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit. Agentes antimicrobianos y quimioterapia 2011; 55(1): 433-5.

Graitcer SB, Gubareva L, Kamimoto L, et al. Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States. Emerging Infect Dis. 2011; 17(2): 255-7.

Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis. 2006; 12(6): 894-9.

Härter G, Zimmermann O, Maier L, Schubert A, Mertens T, Kern P, Wöhrle J. Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus. Clin Infect Dis. 1 de mayo de 2010;50(9):1249-51.

Havers F, Thaker S, Clippard J, et al. Use of influenza antiviral agents by ambulatory care clinicians during the 2012-2013 influenza season. Clin Infect Dis. 2014;59:774-782.

Hernan MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Enfermedades infecciosas: una publicación oficial de la Sociedad Estadounidense de Enfermedades Infecciosas 2011; 53(3): 277-9.

Hiba V, Chowers M, Levi-Vinograd I, Rubinovitch B, Leibovici L, Paul M. Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): retrospective cohort study. The Journal of antimicrobial chemotherapy 2011; 66(5): 1150-5.

Hsu J, Santesso N, Mustafa R, Brozek J, Chen YL, Hopkins JP, Cheung A, Hovhannisyan G, Ivanova L, Flottorp SA, Saeterdal I, Wong AD, Tian J, Uyeki TM, Akl EA, Alonso-Coello P, Smaill F, Schünemann HJ. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med. 3 de abril de 2012;156(7):512-24.

Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, Leang SK, Lee RT, Iannello P, Gehrig N, Shaw R, Wark P, Caldwell N, Givney RC, Xue L, Maurer-Stroh S, Dwyer DE, Wang B, Smith DW, Levy A, Booy R, Dixit R, Merritt T, Kelso A, Dalton C, Durrheim D, Barr IG. Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. J Infect Dis. 15 de julio del 2012;206(2):148-57.

Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, Gehrig N, Kelso A. Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N Engl J Med. 29 de diciembre del 2011;365(26):2541-2.

Hurt AC, Chotpitayasunondh T, Cox NJ, Daniels R, Fry AM, Gubareva LV, Hayden FG, Hui DS, Hungnes O, Lackenby A, Lim W, Meijer A, Penn C, Tashiro M, Uyeki TM, Zambon M; WHO Consultation on Pandemic Influenza A (H1N1) 2009 Virus Resistance to Antivirals. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis. marzo de 2012;12(3):240-8.

Jefferson T, Jones MA, Doshi P, Del Mar CB, Heneghan CJ, Hama R, Thompson MJ. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 18 de enero del 2012;1:CD008965.

Jefferson T, Jones M, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2014 Apr 10;(4):CD008965

Jittamala P, Pukrittayakamee S, Tarning J, et al. Pharmacokinetics of orally administered oseltamivir in healthy obese and non-obese Thai subjects. Agentes antimicrobianos y quimioterapia 2014; 58(3): 1615-21.

Kidd IM, Down J, Nastouli E, Shulman R, Grant PR, Howell DC, Singer M. H1N1 pneumonitis treated with intravenous zanamivir. Lancet. 19 de sept. de 2009;374(9694):1036.

Kimberlin DW, Acosta EP, Prichard MN, et al. Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza. J Infect Dis. 2013; 207(5): 709-20.

Kohno S, Kida H, Mizuguchi M, et al. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Agentes antimicrobianos y quimioterapia 2010; 54(11)4568-74.

Komeda T, Ishii S, Itoh Y, et al. Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir (II): A pediatric drug use investigation. Agentes antimicrobianos y quimioterapia 2015; 21(3):194-201.

Kromdijk W, Sikma MA, van den Broek MP, et al. Pharmacokinetics of oseltamivir carboxylate in critically ill patients: each patient is unique. Intensive Care Med. 2013; 39(5): 977-8.

Kumar D, Morris MI, Kotton CN, et al. Guidance on novel influenza A/H1N1 in solid organ transplant recipients. Am J Transplant. 2010; 10(1): 18-25.

Lackenby A, Moran Gilad J, Pebody R, et al. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11. Euro Surveill. 2011; 16(5).

Lee N, Hui DS, Zuo Z, et al. A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections. Clin Infect Dis. 2013; 57(11): 1511-9.

Lemaitre F, Luyt CE, Roullet-Renoleau F, et al. Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza. Ther Drug Monit. 2012; 34(2): 171-5.

L'Huillier AG, Abed Y, Petty TJ, Cordey S, Thomas Y, Bouhy X, Schibler M, Simon A, Chalandon Y, van Delden C, Zdobnov E, Boquete-Suter P, Boivin G, Kaiser L. E119D Neuraminidase Mutation Conferring Pan-Resistance to Neuraminidase Inhibitors in an A(H1N1)pdm09 Isolate From a Stem-Cell Transplant Recipient. J Infect Dis. 17 de mayo de 2015. pii: jiv288. [publicación electrónica previa a la edición impresa]

Lipsitch M, Hernan MA. Efecto del oseltamivir en complicaciones de las vías respiratorias inferiores tratadas con antibióticos en participantes del ensayo aleatorio con resultado positivo en las pruebas virológicas. Enfermedades infecciosas: una publicación oficial de la Sociedad Estadounidense de Enfermedades Infecciosas 2013; 57(9): 1368-9.

Louie, JK, Lampiris H. Tratar la influenza con inhibidores de la neuraminidasa. ¿Qué es la evidencia? JAMA Internal Medicine. Publicado en Internet el 19 de octubre de 2015.

Louie JK, Yang S, Acosta M, Yen C, Samuel MC, Schechter R, Guevara H, Uyeki TM. Treatment With Neuraminidase Inhibitors for Critically Ill Patients With Influenza A (H1N1)pdm09. Clin Infect Dis. noviembre del 2012;55(9):1198-204.

Louie J, Yang S, Samuel M, Uyeki T, Schechter R. Neuraminidase Inhibitors for Critically Ill Children With Influenza. Pediatría. 2013; 132(6): e1539-45.

Marra F, Chong M, Henry B, Patrick DM, Kendall P. Efectividad de los inhibidores de neuromidasa en la prevención de las hospitalizaciones durante la pandemia de influenza H1N1 en Columbia Británica, Canadá. The Journal of antimicrobial chemotherapy 2013.

McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis. 2007; 45(12): 1568-75.

Memoli MJ, Hrabal RJ, Hassantoufighi A, et al. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis. 2010; 50(9):1252-5.

Moore C, Galiano M, Lackenby A, Abdelrahman T, Barnes R, Evans MR, Fegan C, Froude S, Hastings M, Knapper S, Litt E, Price N, Salmon R, Temple M, Davies E. Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit. J Infect Dis. 1 de enero del 2011;203(1):18-24.

Mulla H, Peek GJ, Harvey C, et al. Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support. Anestesia y cuidado intensivo. 2013; 41(1): 66-73.

Muthuri SG, Myles PR, Venkatesan S, et al. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-10 influenza A(H1N1) pandemic: a systematic review and metaanalysis in hospitalized patients. J Infect Dis. 2013 Feb; 207(4): 553-63.

Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. Mayo de 2014; 2(5):395-404.

Institutos Nacionales de la Salud. Registro de pruebas clínicas con apoyo federal y privado realizadas en los Estados Unidos y en el mundo.

Nguyen HT, Fry AM, Gubareva LV. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir Ther. 2012;17(1 Pt B):159-73.

Nguyen HT, Sheu TG, Mishin VP, Klimov AI, Gubareva LV. Evaluación de la susceptibilidad del virus de la influenza pandémica y estacional A (H1N1) a los inhibidores de la neuraminidasa en tres ensayos de la inhibición de la actividad enzimática. Agentes antimicrobianos y quimioterapia 2010; 54(9):3671-7.

Nguyen HT, Trujillo AA, Sheu TG, et al. Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States. Antivir Res. 2012; 93(3):381-6.

Pai MP, Lodise TP, Jr. Farmacocinética de oseltamivir y oseltamivir carboxilato en adultos obesos: no es necesaria la modificación de la dosis conforme al peso. Agentes antimicrobianos y quimioterapia 2011; 55(12): 5640-5.

Randolph AG, Vaughn F, Sullivan R, et al. Critically ill children during the 2009-2010 influenza pandemic in the United States. Pediatrics. Diciembre de 2011; 128(6):e1450-8. doi: 10.15/peds.2011-0774. Publicación electrónica, 7 de noviembre del 2011.

Rasmussen SA, Jamieson DJ, Macfarlane K, et al. Pandemic influenza and pregnant women: summary of a meeting of experts. Am J Public Health. 2009; 99(Suppl 2): S248-54.

Rasmussen SA, Kissin DM, Yeung LF, et al. Preparing for influenza after 2009 H1N1: special considerations for pregnant women and newborns. American journal of obstetrics and gynecology 2011; 204(6 Suppl 1): S13-20.

Seo S, Englund JA, Nguyen JT, et al. Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics. Terapia antiviral 2013; 18(3): 377-86.

Red de Investigación Clínica de Enfermedades Infecciosas del Sureste de Asia Efecto de la dosis doble de oseltamivir en los resultados clínicos y virológicos entre niños y adultos hospitalizados por enfermedad grave de influenza: ensayo aleatorio, doble ciego, controlado. BMJ. 2013; 346: f3039.

Stephenson I, Democratis J, Lackenby A, McNally T, Smith J, Pareek M, Ellis J, Bermingham A, Nicholson K, Zambon M. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis. 15 de febrero de 2009;48(4):389-96.

Takashita E, Ejima M, Itoh R, et al. A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013. Euro Surveill. 2014; 19(1).

Takashita E, Fujisaki S, Kishida N, et al. Characterization of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and post-pandemic periods in Japan. Influenza Other Respir Viruses. 2013; 7(6):1390-9.

Tamura D, DeBiasi RL, Okomo-Adhiambo M, Mishin VP, Campbell AP, Loechelt B, Wiedermann BL, Fry AM, Gubareva LV. Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir. 5 de mayo de 2015. J Infect Dis. pii: jiv245. [publicación electrónica previa a la edición impresa]

Thorne-Humphrey LM, Goralski KB, Slayter KL, et al. Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial). J Antimicrob Chemother. 2011; 66(9): 2083-91.

Viasus D, Paño-Pardo JR, Pachón J, et al. Novel Influenza A(H1N1) Study Group of the Spanish Network for Research in Infectious Diseases (REIPI). Timing of oseltamivir administration and outcomes in hospitalized adults with pandemic 2009 influenza A(H1N1) virus infection. Chest. octubre de 2011;140(4):1025-32.

Whitley R, Laughlin A, Carson S, et al. Single dose peramivir for the treatment of acute seasonal influenza: integrated analysis of efficacy and safety from two placebo-controlled trials. Antivir Ther. 2014; doi: 10.39/IMP2874. Publicación electrónica previa a la edición impresa.

Yang SG, Cao B, Liang LR, et al. National Influenza A Pandemic (H1N1) 2009 Clinical Investigation Group of China. Antiviral therapy and outcomes of patients with pneumonia caused by influenza A pandemic (H1N1) virus. PLoS One. 2012;7(1):e29652.

Yokota RT, Skalinski LM, Igansi CN, et al. Risk factors for death from pandemic (H1N1) 2009, southern Brazil. Emerg Infect Dis., Agosto de 2011;17(8):1467-71. doi: 10.32/eid1708.101233.

Yu H, Feng Z, Uyeki TM, Liao Q, Zhou L, Feng L, Ye M, Xiang N, Huai Y, Yuan Y, Jiang H, Zheng Y, Gargiullo P, Peng Z, Feng Y, Zheng J, Xu C, Zhang Y, Shu Y, Gao Z, Yang W, Wang Y. Risk factors for severe illness with 2009 pandemic influenza A (H1N1) virus infection in China. Clin Infect Dis. 15 de febrero de 2011;52(4):457-65.

 Arriba

A continuación figuran las referencias citadas en Agentes antivirales para el tratamiento y la quimioprofilaxis de la influenza - Recomendaciones del Comité Asesor sobre Prácticas de Inmunización (ACIP, por sus siglas en inglés).
Versión en PDF [1 MB, 28 páginas]

 

  1. Monto AS, Kioumehr F. The Tecumseh study of respiratory illness. IX. Occurrence of influenza in the community, 1966--1971. Am J Epidemiol 1975;102:553--63.
  2. Glezen PF, Couch RB. Interpandemic influenza in the Houston area, 1974--76. N Engl J Med 1978;298:587--92.
  3. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004;292:1333--40.
  4. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179--86.
  5. CDC. Muertes relacionadas con la pandemia de influenza A 2009 (H1N1) en nativos de Alaska/tribus indígenas de Estados Unidos - 12 estados, 2009. MMWR 2009;58:1341--4.
  6. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with H1N1 2009 influenza in the United States, abril-junio de 2009. N Engl J Med 2009;361:1935--44.
  7. Louie JK, Acosta M, Winter K, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 2009;302:1896--902.
  8. Morgan OW, Bramley A, Fowlkes A, et al. Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A(H1N1) disease. PLoS ONE 2010;5:e9694.
  9. Keren R, Zaoutis TE, Bridges CB, et al. Neurological and neuromuscular disease as a risk factor for respiratory failure in children hospitalized with influenza infection. JAMA 2005;294:2188--94.
  10. Poehling KA, Edwards KM, Weinberg GA, et al. The underrecognized burden of influenza in young children. N Engl J Med 2006;355:31--40.
  11. CDC. Prevención y control de la influenza con vacunas: recomendaciones del Comité Asesor sobre Prácticas de Vacunación (ACIP, por sus siglas en inglés), 2010. MMWR 2010;59(N° RR-8).
  12. Siston AM, Rasmussen SA, Honein MA, et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA 2010;303:1517--25.
  13. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999;341:1336--43.
  14. Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N Engl J Med 2000;343:1282--9.
  15. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med 1997;337:874--80.
  16. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999;180:254--61.
  17. Monto AS, Robinson DP, Herlocher ML, et al. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999;282:31--5.
  18. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001;285:748--54.
  19. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000;355:1845--50.
  20. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000;283:1016--24.
  21. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001;20:127--33.
  22. Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003;163:1667--72.
  23. McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007;45:1568--75.
  24. Creanga AA, Johnson TF, Graitcer SB, et al. Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women. Obstet Gynecol 2010;115:717--26.
  25. Louie JK, Acosta M, Jamieson DJ, et al. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med 2009;362:27--35.
  26. Lee N, Chan PK, Choi KW, et al. Factors associated with early hospital discharge of adult influenza patients. Antivir Ther 2007;12:501--8.
  27. Lee N, Cockram CS, Chan PKS, et al. Antiviral treatment for patients hospitalized with severe influenza infection may affect clinical outcomes. Clin Infect Dis 2008;46:1323--4.
  28. CDC. Recomendaciones provisionales actualizadas para el uso de medicamentos antivirales en el tratamiento y la prevención de la influenza durante la temporada 2009-10. Atlanta, GA: Departamento de Salud y Servicios Humanos de los EE. UU., CDC; 2009.
  29. Brankston G, Gitterman L, Hirji Z, et al. Transmission of influenza A in human beings. Lancet Infect Dis 2007;7:257--65.
  30. Bell DM. Non-pharmaceutical interventions for pandemic influenza, international measures. Emerg Infect Dis 2006;12:81--7.
  31. Moser MR, Bender TR, Margolis HS, et al. An outbreak of influenza aboard a commercial airliner. Am J Epidemiol 1979;110:1--6.
  32. Klontz KC, Hynes NA, Gunn RA, et al. An outbreak of influenza A/Taiwan/1/86 (H1N1) infections at a naval base and its association with airplane travel. Am J Epidemiol 1989;129:341--8.
  33. Hall CB. The spread of influenza and other respiratory viruses: complexities and conjectures. Clin Infect Dis 2007;45:353--9.
  34. Tellier R. Review of aerosol transmission of influenza A virus. Emerg Infect Dis 2006;12:1657--62.
  35. Wong BC, Lee N, Li Y, et al. Possible role of aerosol transmission in a hospital outbreak of influenza. Clin Infect Dis 2010;51:1176--83.
  36. Cox NJ, Subbarao K. Influenza. Lancet 1999;354:1277--82.
  37. Cowling BJ, Fang VJ, Riley S, et al. Estimation of the serial interval of influenza. Epidemiology 2009;20:344--7.
  38. Cowling BJ, Chan KH, Fang VJ, et al. Comparative epidemiology of pandemic and seasonal influenza A in households. N Engl J Med 2010;362:2175--84.
  39. Carrat F, Vergu E, Ferguson NM, et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 2008;167:775--85.
  40. Hayden FG, Fritz R, Lobo MC, et al. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest 1998;101:643--9.
  41. Hall CB, Douglas RG Jr. Nosocomial influenza infection as a cause of intercurrent fevers in infants. Pediatrics 1975;55:673--7.
  42. Giannella M, Alonso M, Viedma DG, et al. Prolonged viral shedding in pandemic influenza A H1N1: clinical significance and viral load analysis in hospitalized patients. Clin Microbiol Infect 2010.
  43. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009;200:492--500.
  44. Frank AL, Taber LH, Wells CR, et al. Patterns of shedding of myxoviruses and paramyxoviruses in children. J Infect Dis 1981;144:433--41.
  45. Klimov AI, Rocha E, Hayden FG, et al. Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J Infect Dis 1995;172:1352--5.
  46. Englund JA, Champlin RE, Wyde PR, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis 1998;26:1418--24.
  47. Boivin G, Goyette N, Bernatchez H. Prolonged excretion of amantadine-resistant influenza a virus quasi species after cessation of antiviral therapy in an immunocompromised patient. Clin Infect Dis 2002;34:E23--5.
  48. Pinsky BA, Mix S, Rowe J, et al. Long-term shedding of influenza A virus in stool of immunocompromised child. Emerg Infect Dis 2010;16:1165--7.
  49. Nicholson KG. Clinical features of influenza. Semin Respir Infect 1992;7:26--37.
  50. Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009;360:2605--15.
 Arriba

51 - 100

  1. Bautista E, Chotpitayasunondh T, Gao Z, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010;362:1708--19.
  2. Cao B, Li XW, Mao Y, et al. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med 2009;361:2507--17.
  3. Douglas R Jr. Influenza in man. En: Kilbourne E, ed. Influenza viruses and influenza. Nueva York, NY: Academic Press, Inc.; 1975:395--418.
  4. Schrag SJ, Shay DK, Gershman K, et al. Multistate surveillance for laboratory-confirmed, influenza-associated hospitalizations in children: 2003--2004. Pediatr Infect Dis J 2006;25:395--400.
  5. Ho YC, Wang JL, Wang JT, et al. Prognostic factors for fatal adult influenza pneumonia. J Infect 2009;58:439--45.
  6. Dagan R, Hall CB. Influenza A virus infection imitating bacterial sepsis in early infancy. Pediatr Infect Dis 1984;3:218--21.
  7. Iwane MK, Edwards KM, Szilagyi PG, et al. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics 2004;113:1758--64.
  8. Chiu SS, Tse CY, Lau YL, et al. Influenza A infection is an important cause of febrile seizures. Pediatrics 2001;108:E63.
  9. McCullers JA, Facchini S, Chesney PJ, et al. Influenza B virus encephalitis. Clin Infect Dis 1999;28:898--900.
  10. Dawood FS, Fiore A, Kamimoto L, et al. Influenza-associated pneumonia in children hospitalized with laboratory-confirmed influenza, 2003--2008. Pediatr Infect Dis J 2010;29:585--90.
  11. Shieh WJ, Blau DM, Denison AM, et al. 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. Am J Pathol 2010;177:166--75.
  12. Libster R, Bugna J, Coviello S, et al. Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina. N Engl J Med 2010;362:45--55.
  13. Kumar A, Zarychanski R, Pinto R, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009;302:1872--9.
  14. Webb SA, Pettila V, Seppelt I, et al. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 2009;361:1925--34.
  15. Lee EH, Wu C, Lee EU, et al. Fatalities associated with the 2009 H1N1 influenza A virus in New York city. Clin Infect Dis 2010;50:1498--504.
  16. Shieh WJ, Blau DM, Denison AM, et al. 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. Am J Pathol 2010;177:166--75.
  17. Ampofo K, Herbener A, Blaschke AJ, et al. Association of 2009 pandemic influenza A (H1N1) infection and increased hospitalization with parapneumonic empyema in children in Utah. Pediatr Infect Dis J 2010;29:905--9.
  18. Jamieson DJ, Honein MA, Rasmussen SA, et al. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet 2009;374:451--8.
  19. Dawood FS, Fiore A, Kamimoto L, et al. Burden of seasonal influenza hospitalization in children, United States, 2003 to 2008. J Pediatr 2010;157:808--14.
  20. Webster RI, Hazelton B, Suleiman J, et al. Severe encephalopathy with swine origin influenza A H1N1 infection in childhood: case reports. Neurology 2010;74:1077--8.
  21. Puzelli S, Buonaguro FM, Facchini M, et al. Cardiac tamponade and heart failure due to myopericarditis as a presentation of infection with the pandemic H1N1 2009 influenza A virus. J Clin Microbiol 2010;48:2298--300.
  22. Peltola V, Ziegler T, Ruuskanen O. Influenza A and B virus infections in children. Clin Infect Dis 2003;36:299--305.
  23. Morishima T, Togashi T, Yokota S, et al. Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect Dis 2002;35:512--7.
  24. Bratincsak A, El-Said HG, Bradley JS, et al. Fulminant myocarditis associated with pandemic H1N1 influenza A virus in children. J Am Coll Cardiol 2010;55:928--9.
  25. Rothberg MB, Haessler SD. Complications of seasonal and pandemic influenza. Crit Care Med 2010;38:e91--7.
  26. Lyon JB, Remigio C, Milligan T, et al. Acute necrotizing encephalopathy in a child with H1N1 influenza infection. Pediatr Radiol 2010;40:200--5.
  27. Lister P, Reynolds F, Parslow R, et al. Swine-origin influenza virus H1N1, seasonal influenza virus, and critical illness in children. Lancet 2009;374:605--7.
  28. Hackett S, Hill L, Patel J, et al. Clinical characteristics of paediatric H1N1 admissions in Birmingham, UK. Lancet 2009;374:605.
  29. Ekstrand JJ, Herbener A, Rawlings J, et al. Heightened neurologic complications in children with pandemic H1N1 influenza. Ann Neurol 2010;68:762--6..
  30. Monto AS, Gravenstein S, Elliott M, et al. Clinical signs and symptoms predicting influenza infection. Arch Intern Med 2000;160:3243--7.
  31. Ohmit SE, Monto AS. Symptomatic predictors of influenza virus positivity in children during the influenza season. Clin Infect Dis 2006;43:564--8.
  32. Boivin G, Hardy I, Tellier G, et al. Predicting influenza infections during epidemics with use of a clinical case definition. Clin Infect Dis 2000;31:1166--9.
  33. Govaert TM, Dinant GJ, Aretz K, et al. The predictive value of influenza symptomatology in elderly people. Fam Pract 1998;15:16--22.
  34. Walsh EE, Cox CFalsey AR. Clinical features of influenza A virus infection in older hospitalized persons. J Am Geriatr Soc 2002;50:1498--503.
  35. v d Hoeven AM, Scholing M, Wever PC, et al. Lack of discriminating signs and symptoms in clinical diagnosis of influenza of patients admitted to the hospital. Infection 2007;35:65--8.
  36. Babcock HM, Merz LRFraser VJ. Is influenza an influenza-like illness? Clinical presentation of influenza in hospitalized patients. Infect Control Hosp Epidemiol 2006;27:266--70.
  37. Neuzil KM, O'Connor TZ, Gorse GJ, et al. Recognizing influenza in older patients with chronic obstructive pulmonary disease who have received influenza vaccine. Clin Infect Dis 2003;36:169--74.
  38. CDC. Pruebas de influenza y prescripción de agentes antivirales---Connecticut, Minesota, Nuevo México y Nueva York, temporada de influenza 2006--07. MMWR 2008;57:61--5.
  39. Katz MA, Lamias MJ, Shay DK, et al. Use of rapid tests and antiviral medications for influenza among primary care providers in the United States. Influenza Other Respi Viruses 2009;3:29--35.
  40. Uyeki TM. Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influenza. Pediatr Infect Dis J 2003;22:164--77.
  41. Schmid ML, Kudesia G, Wake S, et al. Prospective comparative study of culture specimens and methods in diagnosing influenza in adults. BMJ 1998;316:275.
  42. Ali T, Scott N, Kallas W, et al. Detection of influenza antigen with rapid antibody-based tests after intranasal influenza vaccination (FluMist). Clin Infect Dis 2004;38:760--2.
  43. Anónimo. Rapid diagnostic tests for influenza. Med Lett Drugs Ther 1999;41:121--2.
  44. Storch GA. Rapid diagnostic tests for influenza. Curr Opin Pediatr 2003;15:77--84.
  45. Grijalva CG, Poehling KA, Edwards KM, et al. Accuracy and interpretation of rapid influenza tests in children. Pediatrics 2007;119:e6--11.
  46. Uyeki TM, Prasad R, Vukotich C, et al. Low sensitivity of rapid diagnostic test for influenza. Clin Infect Dis 2009;48:e89--92.
  47. Steininger C, Redlberger M, Graninger W, et al. Near-patient assays for diagnosis of influenza virus infection in adult patients. Clin Microbiol Infect 2009;15:267--73.
  48. Hurt AC, Alexander R, Hibbert J, et al. Performance of six influenza rapid tests in detecting human influenza in clinical specimens. J Clin Virol 2007;39:132--5.
  49. Rahman M, Vandermause MF, Kieke BA, et al. Performance of Binax NOW Flu A and B and direct fluorescent assay in comparison with a composite of viral culture or reverse transcription polymerase chain reaction for detection of influenza infection during the 2006 to 2007 season. Diagn Microbiol Infect Dis 2008;62:162--6.
  50. Ruest A, Michaud S, Deslandes S, et al. Comparison of the Directigen flu A+B test, the QuickVue influenza test, and clinical case definition to viral culture and reverse transcription-PCR for rapid diagnosis of influenza virus infection. J Clin Microbiol 2003;41:3487--93.
 Arriba

101 - 150

  1. Blyth CC, Iredell JR, Dwyer DE. Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009;361:2493.
  2. Kok J, Blyth CC, Foo H, et al. Comparison of a rapid antigen test with nucleic acid testing during cocirculation of pandemic influenza A/H1N1 2009 and seasonal influenza A/H3N2. J Clin Microbiol 2009;48:290--1.
  3. Louie JK, Guevara H, Boston E, et al. Rapid influenza antigen test for diagnosis of pandemic (H1N1) 2009. Emerg Infect Dis 2010;16:824--6.
  4. CDC. Guía provisional para medidas de control de infecciones por influenza H1N1 2009 en ámbitos de cuidados de salud, incluyendo la protección del personal de los cuidados de salud. Atlanta, GA: Departamento de Salud y Servicios Humanos de los EE. UU., CDC; 2010. Ingresado el 16 de diciembre del 2010.
  5. Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children---diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1003--32.
  6. Sociedad Estadounidense de Enfermedades Infecciosas. Influenza H1N1: preguntas y respuestas con opinión de expertos de primera línea. Arlington, VA: Sociedad Estadounidense de Enfermedades Infecciosas; 2009. Ingresado el 16 de diciembre del 2010.
  7. Departamento de Salud y Servicios Humanos de los EE. UU. La FDA presenta una nueva prueba de los CDC para detectar la influenza en humanos. Washington, DC: Departamento de Salud y Servicios Humanos de los EE. UU.; 2008.
  8. CDC. Los CDC emiten recomendaciones provisionales para el uso de medicamentos antivirales para la influenza en entornos donde circulan virus de la influenza A (H1N1) e influenza estacional 2008-09 resistentes al oseltamivir. Atlanta, GA: Departamento de Salud y Servicios Humanos de los EE. UU., CDC; 2008. Ingresado el 16 de diciembre del 2010.
  9. Focus Diagnostics. Prueba Simplexa para la influenza A(H1N1) 2009. Cypress, CA: Focus Diagnostics; 2010. Ingresado el 16 de diciembre del 2010.
  10. CDC. FluView: semana que finaliza el 20 de mayo de 2010. Atlanta, GA: Departamento de Salud y Servicios Humanos de los EE. UU., CDC; 2010. Ingresado el 16 de diciembre del 2010.
  11. Baz M, Abed Y, Papenburg J, et al. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N Engl J Med 2009;361:2296--7.
  12. Le QM, Wertheim HF, Tran ND, et al. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N Engl J Med 2010;362:86--7.
  13. CDC. Actualización: actividad de la influenza --- Estados Unidos, temporada 2009--10. MMWR 2010;59:901--8.
  14. CDC. Contagio del virus de la nueva influenza A (H1N1) resistente a oseltamivir en dos pacientes inmunodeprimidos---Seattle, Washington, 2009. MMWR 2009;58:893--6.
  15. CDC. Contagio de influenza pandémica A (H1N1) de 2009, resistente al oseltamivir, en dos campistas que recibieron tratamiento profiláctico, Carolina del Norte, 2009. MMWR 2009;58:969--72.
  16. Roche Laboratories Inc. Tamiflu (fosfato de oseltamivir) como suspensión oral y cápsulas [instrucciones de empleo]. Nutley, NJ: Roche laboratories, Inc.; 2009.
  17. Gubareva LV, Kaiser L, Matrosovich MN, et al. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 2001;183:523--31.
  18. Gubareva LV, Matrosovich MN, Brenner MK, et al. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998;178:1257--62.
  19. Barnett JM, Cadman A, Gor D, et al. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob Agents Chemother 2000;44:78--87.
  20. Stephenson I, Democratis J, Lackenby A, et al. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis 2009;48:389--96.
  21. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004;364:759--65.
  22. Hatakeyama S, Sugaya N, Ito M, et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 2007;297:1435--42.
  23. Stephenson I, Democratis J, Lackenby A, et al. neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza a and b in children. Clin Infect Dis 2009;48:389--96.
  24. CDC. Actualización: actividad de la influenza --- Estados Unidos, 30 de agosto de 2009 - 27 de marzo de 2010, y composición de la vacuna contra la influenza 2010--11. MMWR 2010;59:423--30.
  25. Inoue M, Barkham T, Leo YS, et al. Emergence of oseltamivir-resistant pandemic (H1N1) 2009 virus within 48 hours. Emerg Infect Dis 2010;16:1633--6.
  26. Gubareva LV, Fry AM. Current challenges in the risk assessment of neuraminidase inhibitor-resistant influenza viruses. J Infect Dis 2010;201:656--8.
  27. Ison MG, Gubareva LV, Atmar RL, et al. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 2006;193:760--4.
  28. Baz M, Abed Y, McDonald J, et al. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis 2006;43:1555--61.
  29. Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med 2003;348:867--8.
  30. van der Vries E, Stelma FF, Boucher CA. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med 2010;363:1381--2.
  31. Nguyen HT, Fry AM, Loveless PA, et al. Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin Infect Dis 2010;51:983--4.
  32. Organización Mundial de la Salud. Influenza A (H1N1) virus resistance to oseltamivir. Ginebra, Suiza: Organización Mundial de la Salud; 2009.
  33. Dharan NJ, Gubareva LV, Meyer JJ, et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009;301:1034--41.
  34. Hauge SH, Dudman S, Borgen K, et al. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007--08. Emerg Infect Dis 2009;15:155--62.
  35. Kramarz P, Monnet D, Nicoll A, et al. Use of oseltamivir in 12 European countries between 2002 and 2007---lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses. Euro Surveill 2009;14.
  36. Meijer A, Lackenby A, Hungnes O, et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007--08 season. Emerg Infect Dis 2009;15:552--60.
  37. Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005;366:1175--81.
  38. Bright RA, Shay DK, Shu B, et al. Adamantane resistance among influenza A viruses isolated early during the 2005--2006 influenza season in the United States. JAMA 2006;295:891--4.
  39. Hedrick JA, Barzilai A, Behre U, et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 2000;19:410--7.
  40. Lalezari J, Campion K, Keene O, et al. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med 2001;161:212--7.
  41. Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother 1999;44(Supl. B):23--9.
  42. MIST (Management of Influenza in the Southern Hemisphere Trialists). Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Lancet 1998;352:1877--81.
  43. Heinonen S, Silvennoinen H, Lehtinen P, et al. Early oseltamivir treatment of influenza in children 1--3 years of age: a randomized controlled trial. Clin Infect Dis 2010;51:887--94.
  44. Sato M, Hosoya M, Kato K, et al. Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors. Pediatr Infect Dis J 2005;24:931--2.
  45. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999;282:1240--6.
  46. Monto AS. Antivirals for influenza in healthy adults. Lancet 2006;367:1571--2; respuesta del autor 1573.
  47. Jefferson T, Demicheli V, Rivetti D, et al. Antivirals for influenza in healthy adults: systematic review. Lancet 2006;367:303--13.
  48. Johnston SL, Ferrero F, Garcia ML, et al. Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma. Pediatr Infect Dis J 2005;24:225--32.
  49. Hanshaoworakul W, Simmerman JM, Narueponjirakul U, et al. Severe human influenza infections in Thailand: oseltamivir treatment and risk factors for fatal outcome. PLoS ONE 2009;4:e6051.
  50. Lee N, Choi KW, Chan PK, et al. Outcomes of adults hospitalised with severe influenza. Thorax 2010;65:510--5.
 Arriba

151 - 200

  1. Chemaly RF, Torres HA, Aguilera EA, et al. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. Clin Infect Dis 2007;44:964--7.
  2. Yu H, Liao Q, Yuan Y, et al. Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China. BMJ 2010;341:c4779.
  3. Farias JA, Fernandez A, Monteverde E, et al. Critically ill infants and children with influenza A (H1N1) in pediatric intensive care units in Argentina. Intensive Care Med 2010;36:1015--22.
  4. Dominguez-Cherit G, Lapinsky SE, Macias AE, et al. Critically ill patients with 2009 influenza A(H1N1) in Mexico. JAMA 2009;302:1880--7.
  5. Hayden FG, Jennings L, Robson R, et al. Oral oseltamivir in human experimental influenza B infection. Antivir Ther 2000;5:205--13.
  6. Glaxo Wellcome Inc. Relenza (zanamivir para inhalación) [instrucciones de empleo]. Research Triangle Park, NC: Glaxo Wellcome, Inc.; 2009.
  7. Sugaya N, Mitamura K, Yamazaki M, et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 2007;44:197--202.
  8. Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003--04 influenza season. Emerg Infect Dis 2006;12:894--9.
  9. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Supl. 2):S27--72.
  10. Mauad T, Hajjar LA, Callegari GD, et al. Lung pathology in fatal novel human influenza A (H1N1) infection. Am J Respir Crit Care Med 2010;181:72--9.
  11. Finelli L, Fiore A, Dhara R, et al. Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection. Pediatrics 2008;122:805--11.
  12. Ariano RE, Sitar DS, Zelenitsky SA, et al. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 2010;182:357--63.
  13. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999;37:471--84.
  14. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008;358:261--73.
  15. Wildschut ED, de Hoog M, Ahsman MJ, et al. Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support. PLoS ONE 2010;5:e10938.
  16. Taylor WR, Thinh BN, Anh GT, et al. Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. PLoS ONE 2008;3:e3410.
  17. Organización Mundial de la Salud. Clinical management of human infection with avian influenza A (H5N1) virus. Ginebra, Suiza: Organización Mundial de la Salud; 2007.
  18. Tramontana AR, George B, Hurt AC, et al. Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis 2010;16:1068--75.
  19. Gaur AH, Bagga B, Barman S, et al. Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. N Engl J Med 2010;362:88--9.
  20. Kidd IM, Down J, Nastouli E, et al. H1N1 pneumonitis treated with intravenous zanamivir. Lancet 2009;374:1036.
  21. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 2009;48(Supl. 1):S3--13.
  22. Yun NE, Linde NS, Zacks MA, et al. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). Virology 2008;374:198--209.
  23. Calfee DP, Peng AW, Cass LM, et al. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother 1999;43:1616--20.
  24. Dulek DE, Williams JV, Creech CB, et al. Use of intravenous zanamivir after development of oseltamivir resistance in a critically ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus. Clin Infect Dis 2010;50:1493--6.
  25. Ison MG, Gnann JW Jr, Nagy-Agren S, et al. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 2003;8:183--90.
  26. Kiatboonsri S, Kiatboonsri CTheerawit P. Fatal respiratory events caused by zanamivir nebulization. Clin Infect Dis 2009;50:620.
  27. National Institutes of Allergy and Infectious Diseases and Biomedical Advanced Research and Development Authority. Taller sobre desarrollo antiviral para la influenza del NIAID: nueva generación, 26--27 de marzo de 2009, resumen de la conferencia [378 KB, 31 páginas]. Ingresado el 16 de diciembre del 2010.
  28. Monto AS, Pichichero ME, Blanckenberg SJ, et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis 2002;186:1582--8.
  29. Bowles SK, Lee W, Simor AE, et al. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999--2000. J Am Geriatr Soc 2002;50:608--16.
  30. Lee VJ, Yap J, Tay JK, et al. Seroconversion and asymptomatic infections during oseltamivir prophylaxis against Influenza A H1N1 2009. BMC Infect Dis 2010;10:164.
  31. Khazeni N, Bravata DM, Holty JE, et al. Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza. Ann Intern Med 2009;151:464--73.
  32. Strong M, Burrows J, Stedman E, et al. Adverse drug effects following oseltamivir mass treatment and prophylaxis in a school outbreak of 2009 pandemic influenza A(H1N1) in June 2009, Sheffield, United Kingdom. Euro Surveill 2010;15:pii/19565.
  33. Jefferson T, Jones M, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev 2010;2:CD001265.
  34. Organización Mundial de la Salud. Update on oseltamivir-resistant influenza A (H1N1) 2009 influenza virus: January 2010. Wkly Epidemiol Rec 2010;85:37--40.
  35. Peters PH Jr, Gravenstein S, Norwood P, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 2001;49:1025--31.
  36. Schilling M, Povinelli L, Krause P, et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine 1998;16:1771--4.
  37. Lee C, Loeb M, Phillips A, et al. Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home. Infect Control Hosp Epidemiol 2000;21:700--4.
  38. LaForce C, Man CY, Henderson FW, et al. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2007;29:1579--90; discusión 1577--8.
  39. Nichols WG, Guthrie KA, Corey L, et al. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004;39:1300--6.
  40. Kitching A, Roche A, Balasegaram S, et al. Oseltamivir adherence and side effects among children in three London schools affected by influenza A(H1N1)v, May 2009---an internet-based cross-sectional survey. Euro Surveill 2009;14:19287.
  41. CDC. Actualización: actividad de la influenza --- Estados Unidos, temporada 2009--10. MMWR 2010;59:901--8.
  42. Gomolin IH, Leib HB, Arden NH, et al. Control of influenza outbreaks in the nursing home: guidelines for diagnosis and management. J Am Geriatr Soc 1995;43:71--4.
  43. Garner JS. Guideline for isolation precautions in hospitals. Comité Asesor sobre Prácticas de Control de Infecciones en Hospitales. Infect Control Hosp Epidemiol 1996;17:53--80.
  44. Bradley SF. Prevención de la influenza en establecimientos de cuidados a largo plazo. Comité de Cuidados a Largo Plazo de la Sociedad Estadounidense de Epidemiología Hospitalaria. Infect Control Hosp Epidemiol 1999;20:629--37.
  45. Arden NH, Patriarca PA, Fasano MB, et al. The roles of vaccination and amantadine prophylaxis in controlling an outbreak of influenza A (H3N2) in a nursing home. Arch Intern Med 1988;148:865--8.
  46. Hota SMcGeer A. Antivirals and the control of influenza outbreaks. Clin Infect Dis 2007;45:1362--8.
  47. Kimberlin DW, Escude J, Gantner J, et al. Targeted antiviral prophylaxis with oseltamivir in a summer camp setting. Arch Pediatr Adolesc Med 2010;164:323--7.
  48. Academia Estadounidense de Pediatría. Influenza. En Pickering LK, ed. Red book: 2009 report of the Committee on Infectious Diseases; Elk Grove Village, IL: Academia Estadounidense de Pediatría; 2009.
  49. Administración de Alimentos y Medicamentos. Finalización de las declaraciones de emergencia que justifican una Autorización de Uso de Emergencia (EUA, por sus siglas en inglés) de ciertos medicamentos antivirales---zanamivir, fosfato de oseltamivir y peramivir [31 KB, 1 página]. Silver Spring, MD: Departamento de Salud y Servicios Humanos de los EE. UU., FDA; 2010. Ingresado el 16 de diciembre del 2010.
  50. Kimberlin DW, Shalabi M, Abzug MJ, et al. Safety of oseltamivir compared with the adamantanes in children less than 12 months of age. Pediatr Infect Dis J 2009;29:195--8.
 Arriba

201 - 234

  1. Organización Mundial de la Salud. WHO guidelines for pharmacological management of pandemic (H1N1) 2009 influenza and other influenza viruses. Ginebra, Suiza: Organización Mundial de la Salud; 2010.
  2. Acosta EP, Jester P, Gal P, et al. Oseltamivir dosing for influenza infection in premature neonates. J Infect Dis 2010;303:563--6.
  3. Academia Estadounidense de Pediatría. Influenza. En: Pickering LK, ed. Red book: 2003 report of the Committee on Infectious Diseases. Elk Grove Village, IL: Academia Estadounidense de Pediatría; 2006.
  4. Forest Pharmaceuticals. Jarabe Flumadine (jarabe de hidrocloruro de rimantadina) [instrucciones de empleo]. St. Louis, MO: Forest Pharmaceuticals; 2001.
  5. Administración de Alimentos y Medicamentos. Declaración de la FDA luego del anuncio de CHPA sobre medicamentos para la tos y resfriados de venta libre para los niños. Silver Spring, MD: Departamento de Salud y Servicios Humanos de los EE. UU., Administración de Alimentos y Medicamentos; 2008. Ingresado el 16 de diciembre del 2010.
  6. CDC: Prevención y control de la influenza: recomendaciones del Comité Asesor sobre Prácticas de Vacunación (ACIP, por sus siglas en inglés). MMWR 2004;53(N° RR-6).
  7. Keyser LA, Karl M, Nafziger AN, et al. Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. Arch Intern Med 2000;160:1485--8.
  8. Soo W. Adverse effects of rimantadine: summary from clinical trials. J Respir Dis 1989;10(Supl.):S26--31.
  9. Rasmussen SA, Jamieson DJBresee JS. Pandemic influenza and pregnant women. Emerg Infect Dis 2008;14:95--100.
  10. Dodds L, McNeil SA, Fell DB, et al. Impact of influenza exposure on rates of hospital admissions and physician visits because of respiratory illness among pregnant women. CMAJ 2007;176:463--8.
  11. Callaghan WM, Chu SY, Jamieson DJ. Deaths from seasonal influenza among pregnant women in the United States, 1998--2005. Obstet Gynecol 2010;115:919--23.
  12. Harris J. Influenza occurring in pregnant women: a statistical study of thirteen hundred and fifty cases. JAMA 1919;72:978--80.
  13. Hartert TV, Neuzil KM, Shintani AK, et al. Maternal morbidity and perinatal outcomes among pregnant women with respiratory hospitalizations during influenza season. Am J Obstet Gynecol 2003;189:1705--12.
  14. Greer LG, Sheffield JS, Rogers VL, et al. Maternal and neonatal outcomes after antepartum treatment of influenza with antiviral medications. Obstet Gynecol 2010;115:711--6.
  15. Cass LM, Efthymiopoulos C, Bey A. Pharmacokinetics of of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 1999;36(Supl. 1):1--11.
  16. Karie S, Launay-Vacher V, Janus N, et al. Pharmacokinetics and dosage adjustment of oseltamivir and zanamivir in patients with renal failure. Nephrol Dial Transplant 2006;21:3606--8.
  17. Robson R, Buttimore A, Lynn K, et al. The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2006;21:2556--62.
  18. Schreuder MF, van der Flier M, Knops NB, et al. Oseltamivir dosing in children undergoing hemodialysis. Clin Infect Dis 2010;50:1427--8.
  19. Soung LS, Ing TS, Daugirdas JT, et al. Amantadine hydrochloride pharmacokinetics in hemodialysis patients. Ann Intern Med 1980;93:46--9.
  20. CDC: Prevención y control de la influenza: recomendaciones del Comité Asesor sobre Prácticas de Vacunación (ACIP, por sus siglas en inglés). MMWR 2005;54(N° RR-8).
  21. Atkinson WL, Arden NH, Patriarca PA, et al. Amantadine prophylaxis during an institutional outbreak of type A (H1N1) influenza. Arch Intern Med 1986;146:1751--6.
  22. Vu D, Peck AJ, Nichols WG, et al. Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study. Clin Infect Dis 2007;45:187--93.
  23. Gravenstein S, Johnston SL, Loeschel E, et al. Zanamivir: a review of clinical safety in individuals at high risk of developing influenza-related complications. Drug Saf 2001;24:1113--25.
  24. Webster A, Boyce M, Edmundson S, et al. Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers. Clin Pharmacokinet 1999;36 Supl. 1:51--8.
  25. Anónimo. New concerns about oseltamivir. Lancet 2007;369:1056.
  26. Blumentals WA, Song X. The safety of oseltamivir in patients with influenza: analysis of healthcare claims data from six influenza seasons. MedGenMed 2007;9:23.
  27. Toovey S, Rayner C, Prinssen E, et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf 2008;31:1097--114.
  28. Tamura D, Miura T, Kikuchi Y. Oseltamivir phosphate in infants under 1 year of age with influenza infection. Pediatr Int 2005;47:484.
  29. Shalabi M, Abughali N, Abzug M, et al., Safety of oseltamivir vs. amantadina of rimantadina in children under 1 year of age [resumen]. Presentado en la 45° reunión anual de la Sociedad Estadounidense de Enfermedades Infecciosas, 4--7 de octubre de 2007; San Diego, California.
  30. Okamoto S, Kamiya I, Kishida K, et al. Experience with oseltamivir for infants younger than 1 year old in Japan. Pediatr Infect Dis J 2005;24:575--6.
  31. Budnitz DS, Lewis LL, Shehab N, et al. CDC and FDA response to risk of confusion in dosing Tamiflu oral suspension. N Engl J Med 2009;361:1913--4.
  32. Daniel MJ, Barnett JMPearson BA. The low potential for drug interactions with zanamivir. Clin Pharmacokinet 1999;36 Supl. 1:41--50.
  33. Duval X, van der Werf S, Blanchon T, et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med 2010;7:e1000362.
  34. Administración de Alimentos y Medicamentos. Procedimientos administrativos para la autorización de uso de emergencia de productos médicos. Silver Spring, MD: Departamento de Salud y Servicios Humanos de los EE. UU., Administración de Alimentos y Medicamentos; 2005. Ingresado el 16 de diciembre del 2010.
 Arriba

Descargo de responsabilidad: Es posible que en este sitio encuentre algunos enlaces que le lleven a contenido disponible sólo en inglés. Además, el contenido que se ha traducido del inglés se actualiza a menudo, lo cual puede causar la aparición temporal de algunas partes en ese idioma hasta que se termine de traducir (generalmente en 24 horas). Llame al 1-800-CDC-INFO si tiene preguntas sobre la influenza estacional, cuyas respuestas no ha encontrado en este sitio. Agradecemos su paciencia.

Arriba